Supernus Pharmaceuticals : 2023 Annual Report
Dear Supernus Stockholder, We are very pleased with our performance in 2023 as we continued to successfully transition from our mature brands and set the stage to...
Stay updated with breaking news from Common Equity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dear Supernus Stockholder, We are very pleased with our performance in 2023 as we continued to successfully transition from our mature brands and set the stage to...
2023 ANNUAL REPORT To Our Shareholders, I want to welcome you to our first annual report...
/PRNewswire/ -- An Illinois utility watchdog group has joined forces with a community that has had highly publicized problems with lead in its drinking water...
CELL-BASED TECHNOLOGY PLATFORMS 2023 Annual Report ...
Net income per diluted share was $1.74 and adjusted after-tax income* per diluted share was $1.77 General Insurance underwriting income increased 19% year-over-year to $596 million, or 67% on a...